Evaxion A (EVAX) Equity Average (2023)
Evaxion A (EVAX) reported Equity Average of $4.1 million for Q2 2023, down 33.52% quarter-over-quarter from $6.1 million in Q1 2023.
Evaxion A (EVAX) Equity Average (2023) Analysis & Trends
Evaxion A has reported Equity Average for 1 years, with the latest figure at $4.1 million in Q2 2023.
- For the quarter ending Q2 2023, Equity Average changed N/A year-over-year to $4.1 million; the trailing twelve-month figure through Jun 2023 stood at $4.1 million (changed N/A YoY), and the FY2025 full-year result was $7.7 million, up 341.14% from the prior year.
- Equity Average for Q2 2023 stood at $4.1 million, down from $6.1 million in the prior quarter.
- The five-year high for Equity Average was $6.1 million in Q1 2023, with the low at $4.1 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 21.35 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 516.41 Mn |
| 10 | Regeneron Pharmaceuticals | 63.59 Bn | 54.83 Bn | 3.31 Bn | 31.34 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 4.05 Mn |
| Mar 31, 2023 | 6.09 Mn |